Stem Cells and Regenerative Therapy
Stem Cells and Regenerative Medicine hold the promise of repairing damaged or injured tissues and stimulating the bodys own healing mechanism. This is accomplished using the latest technologies to help the body heal. Stem cells and Regenerative Medicine provide effective solutions that heal the body from within. Midwest Integrated Medical Center in Hudson, Wisconsin is proud to be a leader in helping patients repair by unlocking the regenerative healing power of the human body!
Sometimes surgery isnt an option for pain relief, or perhaps, previous treatments havent worked. In such instances, stem cell and regenerative medicine techniques may be a solution. Pain-relief experts at Midwest Integrated Medical Center can evaluate whether youre a candidate for regenerative medicine. This comprehensive alternative treatment is beneficial for chronic pain sufferers of knee pain, shoulder pain, hip pain, wrist pain, elbow pain, arthritis, and so much more. Book your stem cells and regenerative medicine consultation appointment today, either online or over the phone.
Stem Cells and Regenerative medicine involves using your body to heal itself, using naturally occurring cells and specialized fluids. Midwest Integrated Medical Center provides patients with amniotic allograft treatments for regenerating healing purposes. These treatments are made up of hyaluronic acid, regenerative cells, and cytokines, which are all powerful growth factors that help regenerate your bodys tissues.
Once youre injected with the amniotic allograft serum, the growth factors start to work, triggering cell growth in the area injected. Over the following few weeks, cells grow and divide, forming new tissues. This helps heal damaged or injured areas you have, without going through a surgical procedure.
Stem Cells and Regenerative medicine with amniotic allograft treatments is beneficial for healing many types of bone and soft tissue problems, including arthritis. The injections may help heal your:
Stem Cells are primitivecells that can develop into any other type of cell in your body. Since they can become any type of cell including muscle, bone or ligament cells, they beginhealing those injured tissues. Your body is continuously rebuilding, and Amniotic Allograft Therapy delivers a high concentration of growth factors into the injured or weaken area which will promote natural healing.
While there have been controversies surrounding the source of stem cells for healing purposes, Midwest Integrated Medical Center is committed to preservingthe value anddignity of human life. We are proud of our partnership with a biologics provider which obtains placental and amniotic stem cells with parental consent from live human births. At the time of Cesarean delivery (also known as C-section), the baby is delivered and the placenta and fluid, which are typically discarded, are saved. All tissues are then tested to ensure viability and safety. Tissues are processed to the highest standards in a state-of-the-art American Association of Tissue Banks (AATB) accredited facility and are subjected to stringent testing prior to release.
Amniotic Allografts are prepared and injected into the damaged or weakened area where they allow the body to heal at an accelerated rate. These growth factors pinpoint the degenerated tissue and heal them by regenerating new cells and tissue. According to Midwest Integrated Medical Providers, patients can experience a remarkable decrease in pain and significant improvement in their range of motion within only a few weeks of one treatment.
Amniotic Allograft Therapy offers hope and healing! Get YOUR life back without painful surgery and costly drugs!
***Because we cannot test the amniotic tissues for stem cells without killing the stem cells in the process we cannot claim there are live stem cells in the Amniotic Allograft. The FDA has deemed this a rule. The company we work with tests four random samples from every placenta they collect. After the Amniotic Allograft has been processed they are cryofrozen to -80 C. When the Amniotic Allograft are then warmed they find 95% of the stem cells are viable, alive and can then go to work. However, because the sample that goes in the patients cannot be tested without killing the stem cells we cannot claim a 95% viability rate. All we can do is show you what happens with patients after being injected with Amniotic Allograft. The theory is that these tissues (cartilage, ligament, tendon, muscles, bone, discs, and nerves) begin to repair themselves.
Our In-Office Procedure
Because you are kickstarting your body into making new tissues, it does take some time for your regenerative medicine treatment to start working. Some patients report a dramatic reduction in their pain levels in as little as two weeks, while others experience improvement within a few months. It just depends on how quickly your body responds to the treatment.
Possibly, depending on how quickly you heal and the severity of your injury. If you see improvement but you dont notice significant improvement, your doctor might suggest repeating the treatment, just to further boost healthy tissue growth. They can let you know what to expect during your consultation and assessment appointment.
They are injections after all, so you may feel a bit of stinging, but only for a few seconds. Most patients describe a temporary burning sensation, although it doesnt last long. If youre sensitive to pain or are getting the injections in a sensitive area, your practitioner can apply a topical numbing product. This product decreases some of the stinging sensation from the injection and minimizes your discomfort.
The use of cellular therapy is a modern new approach, which can address both the inflammation and degeneration in hopes of providing a non-surgical repair for the patient. Live cell allogenic amniotic fluid is a rich source of epithelial progenitor cells and mesenchymal cells and carries an intrinsic antibacterial component. The factors contained in this medium will provides a matrix which solves both the acute inflammation issue as well as the long-term degeneration issue, which will ultimately lead to fewer cases that go on to surgery and more cases that will return to full function and normal activities of daily living. This is an active and growing field of medicine that does have a lack of understanding by many of the insurance carriers, adjusters, and other medical professionals, but when this therapy is applied judiciously to the proper candidates has profound positive results.
The use of biologic tissue transplants offers an improved quality of life for many surgical patients. As advances in the procurement and processing of biologics continue to evolve, and the numbers and types of biologic tissue forms continue to expand, so do the challenges related to tissue management and compliance with all applicable regulations and guidelines.
PalinGen products follow all appropriate guidelines, in testing as well as processing and ultimately delivery of a healthy viable allograft to the patient to amplify tissue regeneration.
The risks of using PalinGen products is exceptionally small, but a very small risk of disease transmission cannot be 100% ruled out, none has ever been reported, no adverse side effects has ever been reported. But within every product, there is some risk, and you are being informed today of all the precautions we take in bringing the product to you, and that a potential risk does exist no matter how small, when this product is used on you or in you.
Call us today 715-808-0716 or to schedule a private consultation with our staff.
You may also book your consultation by clicking below.
See the original post:
Stem Cell Therapy And Regenerative Medicine : Midwest ...
- US FDA Approves Naxitamab for the Treatment of Neuroblastoma - OncoZine - November 29th, 2020
- Coronavirus treatments and vaccines. Here are the latest developments - San Francisco Chronicle - November 29th, 2020
- Dr Apar Kishor Ganti Outlines the Effectiveness of Lurbinectedin and Benefits Over Competition - AJMC.com Managed Markets Network - November 26th, 2020
- Commonly used antibiotic shows promise for combating Zika infections - National Institutes of Health - November 26th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 26th, 2020
- Global Cell Harvesting Market to Reach US$381,4 Million by the Year 2027 - Salamanca Press - November 26th, 2020
- Tanya Siddiqi, MD, Discusses the Promise of Reduced Toxicity With Liso-Cel - AJMC.com Managed Markets Network - November 26th, 2020
- Tetracycline-based Antibiotics Show Promise for Combating Zika Infections - Global Biodefense - November 26th, 2020
- Study Suggests AYAs Treated for AML Have High Risk of Developing Long-Term Complications - Cancer Network - November 26th, 2020
- Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment... - November 26th, 2020
- Study Finds Racial and Ethnic Disparities in Treatment of AL Amyloidosis - DocWire News - November 22nd, 2020
- New Virtual Reality Tool, Domestic Cats are SARS-CoV-2 Carriers, Combination Therapy Advances: COVID-19 Updates - Bio-IT World - November 22nd, 2020
- SEE | Smoking worsens Covid-19 infection in the airways, new study reveals - Health24 - November 22nd, 2020
- Could Cell Therapy Be The Answer To COVID-19? - CBS Boston - November 3rd, 2020
- CA Prop 14 Explained: What To Know Before You Vote Election Day - Los Angeles, CA Patch - November 3rd, 2020
- GMP Cell Banking Services Market Predicted to Accelerate the Growth by 2019-2029 - TechnoWeekly - November 3rd, 2020
- Making Progress Against Relapsed/ Refractory DLBCL Without CAR T - OncLive - November 3rd, 2020
- Orchard Therapeutics to Host Virtual R&D Investor Event on Friday, November 13, 2020 - GlobeNewswire - November 3rd, 2020
- Editorial Article: Combating cancer: The incubation technology accelerating CAR-T cell therapy development - SelectScience - October 31st, 2020
- Richters Transformation: When a Slow-Growing Cancer Turns Aggressive - SurvivorNet - October 31st, 2020
- Detroit Pistons, Make-A-Wish put a smile on the face of Commerce Township boy - The Oakland Press - October 31st, 2020
- NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia - Yahoo Finance - October 31st, 2020
- HBS and Harvard's Department of Stem Cell and Regenerative Biology Receive $25 Million Gift from The Chris and Carrie Shumway Foundation to Support... - October 23rd, 2020
- Harnessing regeneration of retinal tissues: An option almost within reach - Ophthalmology Times - October 23rd, 2020
- Fate Therapeutics' and Celyad's CAR therapies in oncology offer potential - pharmaceutical-technology.com - October 23rd, 2020
- World Wide Stem Cell Treatment Centers Provides Exceptional Regenerative Treatment Options To Those in Need - GlobeNewswire - October 16th, 2020
- Proposition 14: Stem cell research bonds City Times - City Times - October 16th, 2020
- BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update - PRNewswire - October 16th, 2020
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 16th, 2020
- Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors - PR Web - October 10th, 2020
- Report of the president: Appointments and promotions | Stanford News - Stanford University News - October 10th, 2020
- UTSW Scientist: 'We Need More Women Thinking Creatively in the Lab and Pushing Science Forward' - dallasinnovates.com - October 10th, 2020
- Here's what is known about Trump's COVID-19 treatment - Science Magazine - October 4th, 2020
- Election Guide: Here's What You Need to Know About Proposition 14 - NBC Bay Area - October 4th, 2020
- ASX up 2.3%, banks and energy outperform - The Sydney Morning Herald - October 4th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies MARKET 2020 |INDUSTRY ANALYSIS, SIZE, SHARE, TRENDS, MARKET DEMAND, GROWTH, OPPORTUNITIES AND... - September 25th, 2020
- Finding The Achilles Heel of A Killer Parasite - Newswise - September 25th, 2020
- SHE Initiative Shines Light on Gender Disparities in Oncology Workforce - Targeted Oncology - September 25th, 2020
- Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in... - September 23rd, 2020
- Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients - Curetoday.com - September 23rd, 2020
- CytoDyn's Phase 2 Study of Leronlimab for Mild-to-Moderate COVID-19 Selected for Oral Presentation at the Special isirv-AVG Virtual Conference on... - September 23rd, 2020
- Opdivo (nivolumab) Demonstrated Superior Disease-Free Survival in Patients with Resected Esophageal or Gastroesophageal Junction Cancer Compared to... - September 23rd, 2020
- Coronavirus Researchers Discover How COVID-19 May Trigger Fatal Levels of Lung Inflammation - SciTechDaily - September 21st, 2020
- The Holistic Sanctuary Announces Exciting Plans to Expand Over Next 4 Years and Save More Lives - PRNewswire - September 21st, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 21st, 2020
- City of Hope Enters Licensing Agreement With Chimeric to Develop Its Pioneering Chlorotoxin CAR T Cell Therapy - Business Wire - September 21st, 2020
- Emerging immunotherapies in multiple myeloma - The BMJ - September 21st, 2020
- ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed... - September 21st, 2020
- Oakland 24-year-old seeking multiethnic bone marrow donor - The Jewish News of Northern California - September 21st, 2020
- First-Line Treatment With Merck's KEYTRUDA (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients... - September 21st, 2020
- Coronavirus, Charity, and the Trolley Problem - Crooked - September 12th, 2020
- Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs - Targeted Oncology - September 1st, 2020
- Royal Biologics Announces the Acquisition of FIBRINET - PRNewswire - September 1st, 2020
- Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape - Targeted Oncology - September 1st, 2020
- MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European... - August 28th, 2020
- The Inside Story Of Biotechs Barnum And His Covid Cures - Forbes - August 28th, 2020
- Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals - Seeking Alpha - August 25th, 2020
- Study sheds light on why retinal ganglion cells are vulnerable to glaucoma - Jill Lopez - August 19th, 2020
- Coronavirus Thursday update: UMN announces new stem cell treatment - TwinCities.com-Pioneer Press - August 15th, 2020
- Health and Fitness: Hip replacement surgery: getting back to what you love - taosnews - August 14th, 2020
- How MC Hammer And Other Performing Artists Are Sharing Their Love Of Science - Forbes - August 12th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 8th, 2020
- Chinese Govt-Compensated Experts Plead Guilty to Thieving Investigation From an American Childrens Medi ... - 90Xtra - August 7th, 2020
- US government considers ethics of aborted tissue research - Angelus News - August 7th, 2020
- Mesa Discusses Treating Myelofibrosis and Other MPNs - Targeted Oncology - August 7th, 2020
- Startup Accelerator: Volumetric Aims to Be the Tissue Bioprinting Farm of the Future - 3DPrint.com - August 6th, 2020
- Cord blood offers hope for rare diseases and ethnic minorities - The Province - August 6th, 2020
- FDA touts advanced manufacturing to address Covid-19 shortfalls - Endpoints News - August 5th, 2020
- Cancer Research Institute Awards $30.2 Million in Grants and Fellowships to Support Basic and Clinical Research in Immunology and Cancer Immunotherapy... - August 5th, 2020
- RenovaCare Appoints Dr. Lydia M. Evans to Its Board of Directors and Increases Board Membership - GlobeNewswire - August 4th, 2020
- MediVet Biologics Rebrands as Ardent Animal Health - Benzinga - August 3rd, 2020
- Church Point Police Captain dies from COVID-19 complications: 'Go and protect the heavens, my dearest friend' - The Advocate - August 1st, 2020
- BMT survivor study finds significant breast cancer risk in young women who received total body irradiation - The Mix - July 31st, 2020
- Hyperbaric Oxygen Therapy Can Enhance Cognition in Healthy Older Adults - PsychCentral.com - July 29th, 2020
- The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo - Explica - July 29th, 2020
- Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy - Press Release - Digital Journal - July 29th, 2020
- COVID-19 Fibroblast Based Cell Therapy Candidate Shown to Reduce Lung Scarring in Aggressive Animal Model - El Paso Inc. - July 25th, 2020
- 'Self-eating' process of stem cells may be the key to new regenerative therapies - 7thSpace Interactive - July 23rd, 2020
- R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - PR Web - July 23rd, 2020
- CAR T-Cell Therapy Offers Potential Solution for Relapse in MCL, But With Toxicity Risk - Targeted Oncology - July 22nd, 2020